In this context, targeting immune checkpoints by blocking programmed cell death 1 (PD‐1) and/or programmed cell death 1 ligand 1 (PD‐L1) is one of the most promising new cancer therapies and has shown to improve progression‐free survival for triple‐negative BC (TNBC) patients [5]. The gene discussed is PDCD1; the disease is cancer.